PTCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PTC Therapeutics Inc (PTCT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. Despite recent price declines and mixed financial performance, the stock shows strong long-term potential due to positive analyst sentiment, hedge fund interest, and strategic growth in rare disease treatments. The oversold RSI and support near current price levels suggest a favorable entry point.
The stock is currently oversold with an RSI of 11.14, indicating a potential rebound. The MACD is negative and expanding, suggesting short-term bearish momentum. Key support levels are at $63.39 and $60.95, close to the current price of $62.205, which could act as a floor for further declines.
Analysts are bullish, with multiple price target increases and Overweight ratings. Price targets range from $75 to $120, significantly above the current price.
Hedge funds are heavily buying, with a 3181.08% increase in buying activity last quarter.
Strategic focus on rare diseases and innovation positions the company for long-term growth.
Recent insider confidence, as seen in Palo Alto Investors LP increasing their stake.
Recent financial performance shows a YoY revenue drop of -22.75%, though net income and EPS have improved.
MACD indicates short-term bearish momentum.
Broader market weakness, with the S&P 500 down -1.54%, may weigh on the stock.
In Q4 2025, revenue dropped by -22.75% YoY to $164.68M. However, net income improved significantly to -$134.97M (+104.85% YoY), and EPS rose to -1.64 (+92.94% YoY). Gross margin slightly declined to 90.1% (-0.78% YoY).
Analysts are overwhelmingly positive, with multiple price target increases and Overweight/Buy ratings. Barclays sees significant upside potential, citing underappreciated opportunities in phenylketonuria and a positive outlook for the biotech sector in 2026. Price targets range from $75 to $120, with the majority above $90.
